Pharma BD Deal Intelligence
A slow-burn integration that gave Baxter a real connected-care and patient-monitoring platform in Hillrom, but the $12.4B price tag loaded on debt just as Baxter's core business hit turbulence—leaving the digital-health payoff overshadowed by balance-sheet strain.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Baxter agreed to acquire Hillrom for $156 per share in cash, with a total enterprise value of approximately $12.4 billion including assumed debt.
Baxter International finalized its $10.5 billion acquisition of Hillrom Holdings, combining two major medical device manufacturers in a significant industry…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Baxter International acquired Hillrom for $156 per share in cash for total equity value of approximately $10.5 billion and enterprise value of approximately $12.4 billion. The deal expanded Baxter's digital health and connected care offerings.
$45.7B Global Market · 7.4% Market CAGR (2022-2030)
Patient monitoring encompasses devices and systems that track vital signs, physiological parameters, and clinical status in hospital and remote settings. Digital health solutions increasingly integrate connectivity, data analytics, and AI to improve clinical workflows and patient outcomes.
The patient monitoring market was dominated by Philips, GE Healthcare, and Medtronic at deal time. Hillrom brought differentiated smart bed systems, respiratory care devices, and connected care platforms that complemented Baxter's infusion therapy and renal care portfolio.
Baxter closed acquisition of Hillrom at $156/share (~$10.5B purchase, ~$12.4B EV including debt).
Q1 2022 revenue grew 26% to $3.7B with Hillrom contributing ~$755M. Synergy targets raised from $250M to $300M.
Baxter recorded $3.1B impairment on Hillrom goodwill and intangibles, citing rising rates and equity declines.
Comprehensive restructuring: new operating model, BioPharma Solutions divestiture, planned Kidney Care separation.
Baxter completed sale of Kidney Care (Vantive) to Carlyle for ~$3.4B net proceeds.
Baxter's Healthcare Systems & Technologies segment (home of the former Hillrom assets) reported ~$705M in Q1 2026 sales, flat on a reported basis and down 2% organically, driven by Front Line Care (Welch Allyn) softness. Hillrom integration expenses and a noncash PP&E impairment continued into 2025. The segment remains within Baxter (no divestiture); the result is consistent with the prior 'Red' verdict on the acquisition.
Hillrom triggered $3.1B goodwill impairment within a year, forced complete corporate restructuring and Kidney Care divestiture.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Baxter International Inc. / Hillrom Holdings Inc. (this deal) | 2021 | $12.4B | 48 |
| Baxter International Inc. / ESI Lederle (Wyeth generic injectable business) | 2002 | $316M | 33 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |